---
title: "Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/301096.SZ.md"
symbol: "301096.SZ"
name: "Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd."
industry: "Life Sciences Tools and Services"
datetime: "2026-05-20T22:52:53.022Z"
locales:
  - [en](https://longbridge.com/en/quote/301096.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/301096.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/301096.SZ.md)
---

# Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ)

## Company Overview

Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. operates as a pharmaceutical technology research and development and services company in China. The company primarily provides drug research and development services; and the transformation of research and development technology results for various pharmaceutical, as well as pharmaceutical research and development investment companies. Its business covers the principal links of drug discovery, pharmaceutical research, clinical trials, customized research and development and production, and registration applications.

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | CN Market |
| Website | [www.hzbio-s.com](https://www.hzbio-s.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: D (0.67)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 0 / 26 |
| Industry Median | B |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 0.00% |  |
| P/B Ratio | 2.72 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6810460691.51 |  |
| Revenue | 591378293.15 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -7.03% | D |
| Profit Margin | -31.89% | E |
| Gross Margin | 45.69% | B |
| Revenue YoY | -42.41% | E |
| Net Profit YoY | -188.75% | E |
| Total Assets YoY | 4.97% | C |
| Net Assets YoY | -6.67% | D |
| Cash Flow Margin | 102.29% | C |
| OCF YoY | -42.41% | E |
| Turnover | 0.15 | D |
| Gearing Ratio | 34.49% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.72",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "6810460691.51",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "591378293.15",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-7.03%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-31.89%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "45.69%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-42.41%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-188.75%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "4.97%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "-6.67%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "102.29%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-42.41%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.15",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "34.49%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -132.58 | 25/26 | - | - | - |
| PB | 2.72 | 8/26 | 2.54 | 2.29 | 2.05 |
| PS (TTM) | 9.60 | 19/26 | 10.60 | 9.65 | 8.34 |
| Dividend Yield | 0.00% | - | 0.80% | 0.76% | 0.74% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | WuXi AppTec (603259.SH) | A | A | C | A | B | B |
| 02 | Pharmaron (300759.SZ) | B | B | C | B | B | B |
| 03 | Chemexpress (688131.SH) | B | B | C | C | B | B |
| 04 | HitGen (688222.SH) | B | A | D | B | C | B |
| 05 | GEMPHARMATECH (688046.SH) | B | B | D | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2025-07-28T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 62.37 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/301096.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/301096.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/301096.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/301096.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**